Dynamic ROS Regulation by TIGAR: Balancing Anti-cancer and Pro-metastasis Effects.
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
10 02 2020
10 02 2020
Historique:
entrez:
13
2
2020
pubmed:
13
2
2020
medline:
17
7
2020
Statut:
ppublish
Résumé
The role of ROS in cancer is complex, with studies demonstrating both pro- and anti-tumor effects. In a pancreatic ductal adenocarcinoma model, ROS limitation through TIGAR has been shown to initially support cancer development but to later become a metabolic liability in metastasizing cells that is counteracted by decreased TIGAR expression.
Identifiants
pubmed: 32049042
pii: S1535-6108(20)30048-9
doi: 10.1016/j.ccell.2020.01.009
pii:
doi:
Substances chimiques
Apoptosis Regulatory Proteins
0
Intracellular Signaling Peptides and Proteins
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-142Commentaires et corrections
Type : CommentOn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Interests S.-M.F. has received funding from Bayer, Merck, and BlackBelt Therapeutics.